MedTrace Logo

R21/Matrix-M in African Children Against Clinical Malaria

NCT04704830 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4800

Last updated 2026-02-23

No results posted yet for this study

Summary

A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria

Conditions

Interventions

BIOLOGICAL

R21/Matrix-M

Adjuvanted malaria vaccine

BIOLOGICAL

Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

Placebo Comparator

Sponsors & Collaborators

  • Institut de Recherche en Sciences de la Sante, Burkina Faso

    collaborator OTHER_GOV

  • Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest

    collaborator OTHER_GOV

  • Malaria Research and Training Center, Bamako, Mali

    collaborator OTHER

  • KEMRI-Wellcome Trust Collaborative Research Program

    collaborator OTHER

  • Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania

    collaborator UNKNOWN

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian VS Hill, PhD · Jenner Institute, University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Months
Max Age
36 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2023-03-21
Completion
2028-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04704830 on ClinicalTrials.gov